134 related articles for article (PubMed ID: 20805677)
1. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin.
Suzuki K; Sugawara Y; Sekine T; Nakase K; Katayama N
J Infect Chemother; 2009 Feb; 15(1):42-5. PubMed ID: 19280300
[TBL] [Abstract][Full Text] [Related]
3. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Terpos E; Politou M; Rahemtulla A
J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
[TBL] [Abstract][Full Text] [Related]
4. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
5. [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Koda Y; Mori T; Shimizu T; Kato J; Yamane A; Sadahira K; Tsukada Y; Yokoyama K; Hashimoto N; Hattori Y; Okamoto S
Rinsho Ketsueki; 2012 Aug; 53(8):760-4. PubMed ID: 22975816
[TBL] [Abstract][Full Text] [Related]
6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
9. Acute pancreatitis caused by bortezomib.
Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
[TBL] [Abstract][Full Text] [Related]
10. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
11. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
14. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
[TBL] [Abstract][Full Text] [Related]
16. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
18. [Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia].
Nagamachi Y; Yamauchi N; Muramatsu H; Okamoto T; Inomata H; Nozawa E; Koyama R; Ihara K; Nishisato T; Yamada H; Yano T; Tanaka S; Ono K; Kikuchi S; Kato J
Rinsho Ketsueki; 2013 May; 54(5):451-6. PubMed ID: 23727683
[TBL] [Abstract][Full Text] [Related]
19. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
